Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
about
A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.Antibody therapy for chronic lymphocytic leukemia.Monoclonal antibody therapy of B cell lymphoma.Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.New drug therapies in peripheral T-cell lymphoma.Cutaneous T-cell lymphomas: a review of new discoveries and treatments.Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group.CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-HodgkiCD52 expression in non-mycotic T- and NK/T-cell lymphomas.Richter's syndrome: a novel presentation.Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity.Alemtuzumab in chronic lymphocytic leukemia.
P2860
Q33337233-AFD61BB0-5D81-442A-B861-7B4B8EE06B7EQ33388189-35512EE2-E7D5-41D0-928A-93A3C63C16E7Q34390288-AF283926-C3C6-4E47-9652-E76A767D72DAQ34589909-3EB00F53-5F64-469C-8288-0ACC6E914F36Q35684872-DDA27F11-5E69-4906-BA13-3DA84B426B23Q35766129-AA7CACF9-9B2A-493B-AE12-4819497DD373Q36194538-8EDBFCF6-68A2-483E-BB01-AF435054629EQ37237469-985B1B83-3928-4203-B0BD-D13E1D3B5682Q37854715-2EE147DF-FD2B-4D64-8FC3-01919423946AQ37981969-3A86D557-862C-4116-B207-52388FBA6618Q38466180-07268FDB-771F-4C19-A06D-F18CFD6C084BQ40037876-4EF8623E-DBB3-4C4F-9B6D-74AFA93E7BE8Q40239088-2F5921B0-606E-4F7C-A955-2481003A8C7CQ40636381-E3B5C774-F328-41FE-AFC0-6B262FB31FF3Q45861931-CCA60AA5-7512-4ECA-A749-DC8B44D00FE5Q46124726-34C306B2-715F-4DF9-A202-6EFAE1056D80Q46719541-8836D2AE-D255-4D34-AD65-5F023F0C384AQ53304621-DA857055-3971-498C-92E6-7A9C9AD3583CQ53572903-B37D0981-6944-4E1E-8A13-37A3334E1AB6
P2860
Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
@en
Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
@nl
type
label
Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
@en
Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
@nl
prefLabel
Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
@en
Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
@nl
P2093
P2860
P356
P1476
Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
@en
P2093
Nethersell AB
Salisbury JR
P2860
P304
P356
10.1136/JCP.47.4.313
P407
P577
1994-04-01T00:00:00Z